Mucopolysaccharidosis Type IV - 47 Studies Found
Enrolling by invitation |
: Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox : Cartilage-hair Hypoplasia : 2015-02-10 : Biological: Varilrix Vaccination against varicella in selected cartilage-hair hypoplasia patients |
Enrolling by invitation |
: BMN 110 Phase 3B in Australian Patients : Mucopolysaccharidosis IVA (Morquio A Syndrome) : 2013-09-10 : Drug: BMN 110 All pateints receive treatment with BMN 110 |
Terminated |
: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation :
: 2012-09-17 : Drug: BMN 110 Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2. |
Terminated |
: Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome :
: 2012-05-24 : |
Completed |
: Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) :
: 2011-12-22 : Drug: BMN 110 Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk o |
Terminated |
: Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA : Mucopolysaccharidosis Type IVA : 2012-11-21 |
Active, not recruiting |
: Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study) :
|
Active, not recruiting |
: Gait Analysis in MPS IVA :
|
Completed |
: A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) : MPS IV A : 2011-01-10 :
|
Completed |
: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) :
|